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Disclosure, or open communication, by female microbicide trial participants of their trial participation and use of an
investigational HIV prevention drug to a sexual partner may affect participants’ trial product usage behavior and
contribute to poor adherence. With mixed results from recent microbicide clinical trials being linked to differing
participant adherence, insights into the communication dynamics between trial participants and their sexual partners are
particularly important. We examined the quantitative association between (1) communication of trial participation to a
partner and participant adherence to gel and (2) communication of trial participation to a partner and participant HIV
status. An in-depth adherence and product acceptability assessment was administered to the women participating in the
CAPRISA 004 trial. Additionally, we collected qualitative data related to communication of trial participation and gel
use. Qualitatively, among 165 women who had reported that they had discussed trial participation with others, most
(68%) stated that they communicated participation to their sexual partner. Most of the women who had communicated
study participation with their partners had received a positive/neutral response from their partner. Some of these women
stated that gel use was easy; only a small number said that gel use was difficult. Among women who did not
communicate their study participation to their partners, difficulty with gel use was more common and some women
stated that they feared communicating their participation. Quantitatively, there was no statistically significant difference
in the proportions of women who had communicated study participation to a partner across different adherence levels or
HIV status. A deeper knowledge of the dynamics surrounding trial participation communication to male partners will be
critical to understanding the spectrum of trial product usage behavior, and ultimately to designing tailored strategies to
assist trial participants with product adherence.
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Introduction
Previous microbicide, diaphragm, and condom studies and
clinical trials have explored barriers women face in
disclosing, or openly communicating, study or trial parti-
cipation to sexual partners including fear of violating trust
or relationship norms, partners’ refusal of study product
use, and physical violence (Gafos et al., 2012; Montgomery
et al., 2008; Montgomery, Gafos et al., 2010; Montgomery,
Cheng et al., 2010; Morrow et al., 2003; Sahin-Hodoglugil
et al., 2006; Sahin-Hodoglugil et al., 2011; Woodsong &
Alleman, 2008; Woodsong et al., 2013). Studies have also
explored linkages between communication of participation
and study product adherence and found more consistent
usage among women whose partners knew of their
participation (Greene et al., 2010; Montgomery et al.,
2008; Montgomery, Gafos et al., 2010; Montgomery,
Cheng et al., 2010; Pistorius et al., 2004; van der Straten
et al., 2008; Woodsong & Alleman, 2008). One study
showed product adherence was more difficult for women
whose partners were not aware of their participation and
product use (Sahin-Hodoglugil et al., 2006).
Study product adherence has been cited as an import-
ant factor in the mixed results seen in recent antiretroviral
(ARV)-based microbicide and HIV prevention trials. The
2010 CAPRISA 004 tenofovir gel microbicide trial in
South Africa demonstrated a 39% reduction in HIV
infections; in secondary analyses, infections were reduced
by 54% among women with high adherence to the study
product (Abdool Karim et al., 2010). Similar dose–
response effects have been observed in other HIV preven-
tion trials including iPrEx (Grant et al., 2010), Partner-
sPrep (Baeten et al., 2012), and TDF2 (Thigpen et al.,
2011). In contrast, two studies with evidence of poor
adherence were unable to demonstrate product effective-
ness (Marrazzo, Ramjee, & Nair, 2013; Van Damme
et al., 2012).
We used a mixed methods approach to explore the
relationships between communication of participation
in the CAPRISA 004 microbicide trial to male sexual
partners, participant HIV status, and use of study
product.
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Methods
The study was approved by FHI 360’s Protection of
Human Subjects Committee in Durham, NC, USA and
the University of KwaZulu-Natal Biomedical Research
Ethics Committee in Durban, South Africa.
Study population
This study was conducted simultaneously with the
CAPRISA 004 microbicide gel clinical trial in KwaZulu-
Natal, South Africa. Participants (n = 277) were recruited
from the CAPRISA 004 study population (n = 889). All
trial participants with a positive HIV test result at their
monthly clinic visit were targeted for recruitment1 and 72
confirmed positive were enrolled. Trial participants with
negative HIV test results were selected randomly (n =
205). Demographics and sexual behavior were similar to
the larger CAPRISA 004 cohort. A detailed description of
the study design has been published elsewhere (MacQueen
et al., 2014).
All participants previously met CAPRISA 004 trial
eligibility criteria (aged 18–40 years, sexually active,
HIV-negative at enrollment, not pregnant, and using a
non-barrier form of contraception). Additionally, women
had to be enrolled in the trial for a minimum of two
months and not be suspended from gel use for three
months prior to their most recent HIV test.
Data collection
A one-time, face-to-face in-depth adherence and gel
acceptability assessment was conducted with participants
in the local language, isiZulu. Topics covered included:
. general feelings about trial participation;
. gel and condom use patterns and challenges;
. communication with others about the trial;
. community perceptions about the trial; and
. beliefs about the gel.
The Timeline Followback (TLFB) method (Carey, Carey,
Maisto, Gordon, & Weinhardt, 2001) was used to
measure gel usage over a three-month recall period.
Adherence was measured by the proportion of vaginal
sex events covered by the prescribed dosage of gel with
0–50% events covered categorized as low, 51–80% as
moderate, and 81–100% as high. Prescribed dosage was
one dose within 12 hours before sex, one dose within 12
hours after sex, and no more than two doses in 24 hours
(Abdool Karim et al., 2010). Recorded interviews were
transcribed by native isiZulu speakers using a standar-
dized transcription protocol (McLellan-Lemal, 2008)
then translated into English. To reduce bias, measures
were taken to prevent interviewers from knowing
participants’ HIV status. However, 10 participants (with
positive HIV test results) divulged their HIV test results
during the interview.
Data analysis
Logistic regression was used to assess the association
between communication of trial participation to a partner
and (1) participant adherence to gel and (2) participant
HIV status.
Qualitative data were coded using a team-based,
data-driven, thematic approach and implemented with
AnSWR qualitative data analysis software. Two coders
separately coded 20% of transcripts and inter-coder
agreement checks were conducted. Discrepancies in
coding were resolved to ensure a minimum of 80%
agreement. Code frequencies and co-occurrences were
examined for trends related to trial participation com-
munication, ease of gel use, and partner’s reaction to
communication of trial participation.
Results
Quantitative findings
Participant demographics and baseline sexual behavior
data are shown in Table 1. Logistic regression analyses
examining the degree to which communication with a
partner predicted adherence level or HIV status failed to
reveal any statistically significant associations (Table 2).
Qualitative findings
In total, 165 (60%) participants discussed communication
of trial participation during their interview. Of these, most
(68%) stated that they had communicated participation in
the trial to at least one sexual partner. A majority of the
communicators (n = 74, 65%) said their partners responded
positively or neutrally. Some (n = 23) said gel use was
easy; only seven described gel use as difficult. Women
reporting positive or neutral partners mentioned the ease of
being able to insert gel in their partner’s presence and
ability to use gel when their partner visited unexpectedly.
Some women said their partners facilitated use by provid-
ing reminders for gel insertion before and after sex and for
trial-related appointments:
Interviewer: Ok, is it difficult to remember to insert
the gel?
Respondent: No, it’s not difficult … Because anyway
I keep my gel where we sleep, then he also reminds me
because he is not someone with a good behavior so that
I get protected from getting the disease.
Of the 165 women who discussed trial participation
communication, 52 (32%) did not communicate trial
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participation to any partner. One-third of non-communica-
tors said that gel use was hard and more than 20% said
they were afraid to communicate. Non-communicators said
they were often unable to use gel when their partner was
present or when their partner visited unexpectedly:
Interviewer: What maybe made you not use the gel even
when you had sex?
Respondent: At other times it’s because you think this
person isn’t coming, you see, all of a sudden, you see
him arriving, then it’s not easy for me to insert this thing
because he doesn’t know that I am using this gel.
They also expressed concern that they would be unable
to hide the product and feared their partner would feel
the cold and wetness of the gel, which may cause
arguments or accusations of cheating. Furthermore, some
said that communication of trial participation would
incite anger from or lead to abandonment by their
partners or that their partners may prohibit gel use:
Respondent: One time my boyfriend asked me “why am
I feeling something water-like in your vagina? Do you
maybe have any disease or you have slept with someone
else? I said, ‘no, I don’t have anything’.” Then he was a
bit angry.
Interviewer: Why are you not telling him that you are
using the gel?
Respondent: No, he would be angry and tell me to stop.
Two additional themes emerged among women who did
not communicate trial participation to any partner: (1)
fear that communication would lead to their partner no
longer using condoms and (2) partial communication of
trial participation. The latter was discussed in two ways:
some women communicated their participation in a
Table 1. Participant demographics and baseline sexual behavior.
Variable HIV+ participants (n = 72) HIV– participants (n = 205)
Demographic characteristics
Mean age (years) 22.7 24.2
Monthly income <R1000 (R = South African Rand) 76.3% 83.4%
Married 2.7% 6.3%
Stable partner 94.4% 89.2%
Sexual behavior at baseline
Mean age at sexual debut (years) 17.1 17.4
Mean number sexual partners (lifetime) 2.9 3.0
Mean age of oldest partner (years, past 30 days) 26.0 27.9
Reported sex in the past 7 days 54.1% 62.4%
Always use condom during sex 33.3% 32.6%
New partner (past 30 days) 0.0% 1.4%
Anal sex (past 30 days) 0.0% 0.4%
Table 2. Results of regression analyses.
Adherence level regressed on communication with a partner
Adherence level Cumulative logistic regression
Communication with partner Participants (n = 271) Low Moderate High OR Lower → higher
No 63 (23%) 14% 33% 52% 1.04
Yes 208 (77%) 14% 35% 51% [95% CI: 0.606, 1.783]
HIV status regressed on communication with a partner
HIV Logistic regression
Communication with partner Participants (n = 277) No Yes OR
No 67 (24%) 73% 27% 0.94
Yes 210 (76%) 74% 26% [95% CI: 0.506, 1.756]
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clinical trial, but did not specify they were inserting a
microbicide into their vagina, while other women
revealed to their partner that they were participating in
a trial that involved gel use, but did not specify the gel
was being studied for HIV prevention:
Respondent: I told him that I am cleaning my bladder, I
didn’t tell him it’s [the gel] purpose.
Discussion
The results described here add to the body of knowledge
around partner communication in the context of an HIV
prevention clinical trial and provide important insights
into women’s successes and challenges adhering to
microbicide gel. In the high HIV prevalence setting of
KwaZulu-Natal, South Africa, the majority of study
participants communicated to their sexual partners that
they were taking part in a microbicide trial. The
qualitative data showed that an important minority of
participants did not communicate their study participa-
tion to their sexual partner(s), and many of these women
also reported difficulties with gel use. We did not find a
statistically significant association between communica-
tion of trial participation and either study product
adherence or HIV status. However, an analysis of data
from all participants interviewed when exiting the
CAPRISA 004 trial found a statistically significant
though moderate relationship between disclosure and
adherence; no relationship was found between disclosure
and either HIV incidence or gel efficacy (Mngadi et al.,
2014). Given the moderate association with adherence, it
is possible that our sample size was too small to detect a
relationship, or that it was obscured by biases in the self-
report measures we used.
This study adds to existing evidence concerning the
important role that communication between partners can
play in supporting the use of products like tenofovir gel
to reduce HIV acquisition in women. Just as importantly,
it highlights the importance of finding ways to support
product adherence among women who are not able to
communicate effectively with their partners about HIV
prevention. No single product adherence strategy can be
applied to all HIV prevention trials or product introduc-
tion campaigns. Guidance is needed to inform adherence
strategies that both involve male partners of those
women who want to communicate their study participa-
tion and that support women who would like to use a
study product without their partner’s knowledge. Moving
forward, we must continue to monitor how communica-
tion dynamics with partners influence trial participants’
ability to adhere to microbicides and other new HIV
prevention technologies like PrEP.
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Note
1. For more details about a description of the HIV testing
algorithm, see Abdool Karim et al. (2010).
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